AN OVERVIEW OF COPD: ITS ADVANCED THERAPEUTIC MANAGEMENT AND CHALLENGES FOR DRUG RELEASE AT THE TARGETED SITE
DOI:
https://doi.org/10.22159/ijap.2025v17i3.53675Keywords:
COPD, GOLD, Particle size, Nanoparticles, Inhaled corticosteroids, DPIs, Advanced therapiesAbstract
Chronic Obstructive Pulmonary Disorder (COPD) is a diverse lung ailment characterized by persistent respiratory symptoms such as coughing, dyspnea, sputum formation, and worsening that causes increased airflow limitation. Globally, COPD ranks third in 2019 and is responsible for 3.23 million deaths. It is a health problem that is brought on by inflammation in the lungs. The respiratory system comprises the trachea, bronchi, larynx, paranasal sinuses, and two lungs. COPD and other Respiratory Disorders (RDs) have dominated research. This review emphasizes the potential of novel treatment strategies for COPD, highlighting advanced therapeutic approaches. It addresses the ongoing challenges associated with the effective delivery of pharmaceuticals to targeted sites while aiming to achieve optimal therapeutic outcomes with reduced dosages. The Global Initiative for Chronic Obstructive Lung Disease (GOLD) Report 2024 categorizes COPD treatments into pharmacological and non-pharmacological interventions. Pharmacological therapies aim to alleviate symptoms, enhance exercise tolerance, reduce exacerbations, and improve health outcomes. These include antibiotics, Long-Acting Beta-Agonist (LABA), Short-Acting Beta-Agonist (SABA), Long-Acting Muscarinic-Antagonists (LAMA), Short-Acting Muscarinic-Antagonists (SAMA), Inhaled Corticosteroids (ICS), and bronchodilators in various formulations. The report also reviews inhaler types and highlights the role of nanoscale drug delivery systems in detecting drug particle deposition in the respiratory tract, along with the characterization and classification of Nanoparticles (NPs) in nanomedicine. In conclusion, contemporary nanoparticles enhance biodistribution, optimize pharmacokinetics, and promote physiological stimulation. They also reduce toxicity and increase the therapeutic index, thereby facilitating the transformation of medication administration for chronic respiratory disorders.
References
Bai Y, Liu Y, SU Z, MA Y, Ren C, Zhao R. Gene editing as a promising approach for respiratory diseases. J Med Genet. 2018;55(3):143-9. doi: 10.1136/jmedgenet-2017-104960, PMID 29301855.
COVID. COVID-19 and vascular disease. EBiomedicine. 2020;58:102966. doi: 10.1016/j.ebiom.2020.102966, PMID 32829782.
Sengupta N, Sahidullah M, Saha G. Lung sound classification using cepstral based statistical features. Comput Biol Med. 2016;75:118-29. doi: 10.1016/j.compbiomed.2016.05.013, PMID 27286184.
Restrictive lung disease: practice essentials pathophysiology etiology. Available from: https://emedicine.com/article/301760-overview?form=social.medscape. [Last accessed on 04 Feb 2025].
Martinez Pitre PJ, Sabbula BR, Cascella M. Restrictive lung disease. Preoperative Assess a Case-Based Approach. 2023:101-6.
Restrictive lung disease: overview eMedicine. Medscape. Available from: https://web.archive.org/web/20081219183106.com/article/301760-overview. [Last accessed on 04 Feb 2025].
Restrictive ventilatory defect. Med. Available from: https://oac.jhmi.edu/res_phys/Encyclopedia/RestrictVentDefect/RestrictVentDefect.HTML. [Last accessed on 04 Feb 2025].
Martinez Pitre PJ, Sabbula BR, Cascella M. Restrictive lung disease. Preoperative Assess a Case-Based Approach. 2023:101-6.
Chronic otructive pulmonary disease (COPD). Available from: https://www.who.int/news-room/fact-sheets/detail/chronic-obstructive-pulmonary-disease-(copd).
Spurzem JR, Rennard SI. Pathogenesis of COPD. Semin Respir Crit Care Med. 2005;26(2):142-53. doi: 10.1055/s-2005-869535, PMID 16088433.
Singh D, Agusti A, Anzueto A, Barnes PJ, Bourbeau J, Celli BR. Global strategy for the diagnosis management and prevention of chronic obstructive lung disease: the gold science committee report 2019. Eur Respir J. 2019;53(5):1900164. doi: 10.1183/13993003.00164-2019, PMID 30846476.
Vogelmeier CF, Criner GJ, Martinez FJ, Anzueto A, Barnes PJ, Bourbeau J. Global strategy for the diagnosis management and prevention of chronic obstructive lung disease 2017 report: gold executive summary. Eur Respir J. 2017;49(3):1700214. doi: 10.1183/13993003.00214-2017, PMID 28182564.
Mac Nee W. Pathology pathogenesis and pathophysiology. Br Med J. 2006;332(7551):1202-4. doi: 10.1136/bmj.332.7551.1202.
Hogg JC, Chu F, Utokaparch S, Woods R, Elliott WM, Buzatu L. The nature of small airway obstruction in chronic obstructive pulmonary disease. N Engl J Med. 2004;350(26):2645-53. doi: 10.1056/NEJMoa032158, PMID 15215480.
Agusti A, Hogg JC. Update on the pathogenesis of chronic obstructive pulmonary disease. N Engl J Med. 2019;381(13):1248-56. doi: 10.1056/NEJMra1900475, PMID 31553836.
MC Donough JE, Yuan R, Suzuki M, Seyednejad N, Elliott WM, Sanchez PG. Small airway obstruction and emphysema in chronic obstructive pulmonary disease. N Engl J Med. 2011;365(17):1567-75. doi: 10.1056/NEJMoa1106955, PMID 22029978.
O Donnell DE, Lam M, Webb KA. Spirometric correlates of improvement in exercise performance after anticholinergic therapy in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 1999;160(2):542-9. doi: 10.1164/ajrccm.160.2.9901038, PMID 10430726.
Gagnon P, Guenette JA, Langer D. International journal of COPD dovepress pathogenesis of hyperinflation in chronic obstructive pulmonary disease. Int J COPD. 2014;2014:9-187.
O Donnell DE, Laveneziana P. The clinical importance of dynamic lung hyperinflation in COPD. COPD J Chronic Obstruct Pulm Dis. 2006;3(4):219-32. doi: 10.1080/15412550600977478, PMID 17361503.
Iyer KS, Newell JD, Jin D, Fuld MK, Saha PK, Hansdottir S. Quantitative dual energy computed tomography supports a vascular etiology of smoking-induced inflammatory lung disease. Am J Respir Crit Care Med. 2016;193(6):652-61. doi: 10.1164/rccm.201506-1196OC, PMID 26569033.
Kovacs G, Agusti A, Barbera JA, Celli B, Criner G, Humbert M. Pulmonary vascular involvement in chronic obstructive pulmonary disease is there a pulmonary vascular phenotype? Am J Respir Crit Care Med. 2018;198(8):1000-11. doi: 10.1164/rccm.201801-0095PP, PMID 29746142.
Zhang L, Liu Y, Zhao S, Wang Z, Zhang M, Zhang S. The incidence and prevalence of pulmonary hypertension in the COPD population: a systematic review and meta-analysis. Int J Chron Obstruct Pulmon Dis. 2022;17:1365-79. doi: 10.2147/COPD.S359873, PMID 35711174.
Kovacs G, Avian A, Bachmaier G, Troester N, Tornyos A, Douschan P. Severe pulmonary hypertension in COPD: impact on survival and diagnostic approach. Chest. 2022;162(1):202-12. doi: 10.1016/j.chest.2022.01.031, PMID 35092746.
Barbera JA, Roca J, Ferrer A, Felez MA, Diaz O, Roger N. Mechanisms of worsening gas exchange during acute exacerbations of chronic obstructive pulmonary disease. Eur Respir J. 1997;10(6):1285-91. doi: 10.1183/09031936.97.10061285, PMID 9192930.
Celli BR, Fabbri LM, Aaron SD, Agusti A, Brook R, Criner GJ. An updated definition and severity classification of chronic obstructive pulmonary disease exacerbations: the rome proposal. Am J Respir Crit Care Med. 2021;204(11):1251-8. doi: 10.1164/rccm.202108-1819PP, PMID 34570991.
Parker CM, Voduc N, Aaron SD, Webb KA, O Donnell DE. Physiological changes during symptom recovery from moderate exacerbations of COPD. Eur Respir J. 2005;26(3):420-8. doi: 10.1183/09031936.05.00136304, PMID 16135722.
Miller J, Edwards LD, Agusti A, Bakke P, Calverley PM, Celli B. Comorbidity systemic inflammation and outcomes in the eclipse cohort. Respir Med. 2013;107(9):1376-84. doi: 10.1016/j.rmed.2013.05.001, PMID 23791463.
Houghton AM. Matrix metalloproteinases in destructive lung disease. Matrix Biol. 2015;44-46:167-74. doi: 10.1016/j.matbio.2015.02.002, PMID 25686691.
Gharib SA, Manicone AM, Parks WC. Matrix metalloproteinases in emphysema. Matrix Biol. 2018 Mar 23;73:34-51. doi: 10.1016/j.matbio.2018.01.018, PMID 29406250.
Siddiqui NA, Mansour MK, Nookala V. Bullous emphysema. StatPearls. Available from: https://www.ncbi.nlm.nih.gov/books/NBK537243/.
Hendrix AY, Kheradmand F. The role of matrix metalloproteinases in development repair and destruction of the lungs. Prog Mol Biol Transl Sci. 2017;148:1-29. doi: 10.1016/bs.pmbts.2017.04.004, PMID 28662821.
Wang Y, XU J, Meng Y. International journal of COPD dovepress role of inflammatory cells in airway remodeling in COPD. Int J COPD. 2018;13–3341.
Rodrigues SO, Cunha CM, Soares GM, Silva PL, Silva AR, Goncalves DE Albuquerque CF. Mechanisms pathophysiology and currently proposed treatments of chronic obstructive pulmonary disease. Pharmaceuticals. 2021;14(10):979. doi: 10.3390/ph14100979, PMID 34681202.
Burgstaller G, Oehrle B, Gerckens M, White ES, Schiller HB, Eickelberg O. The instructive extracellular matrix of the lung: basic composition and alterations in chronic lung disease. Eur Respir J. 2017;50(1):1601805. doi: 10.1183/13993003.01805-2016, PMID 28679607.
MC Donough JE, Yuan R, Suzuki M, Seyednejad N, Elliott WM, Sanchez PG. Small airway obstruction and emphysema in chronic obstructive pulmonary disease. N Engl J Med. 2011;365(17):1567-75. doi: 10.1056/NEJMoa1106955, PMID 22029978.
Rodrigues SO, Cunha CM, Soares GM, Silva PL, Silva AR, Goncalves DE Albuquerque CF. Mechanisms pathophysiology and currently proposed treatments of chronic obstructive pulmonary disease. Pharmaceuticals (Basel). 2021;14(10):979. doi: 10.3390/ph14100979, PMID 34681202.
Buist AS, MC Burnie MA, Vollmer WM, Gillespie S, Burney P, Mannino DM. International variation in the prevalence of COPD (The BOLD Study): a population-based prevalence study. Lancet. 2007;370(9589):741-50. doi: 10.1016/S0140-6736(07)61377-4, PMID 17765523.
GOLD report global initiative for chronic obstructive lung disease gold. Available from: https://goldcopd/.org/2024-gold-report.
2023 GOLD report global initiative for chronic obstructive lung disease gold. Available from: https://goldcopd/.org/2023-gold-report-2.
Chronic obstructive pulmonary disease (COPD). Available from: https://www.who.int/news-room/fact-sheets/detail/chronic-obstructive-pulmonary-disease-(copd).
Miravitlles M, Soler Cataluna JJ, Calle M, Molina J, Almagro P, Quintano JA. Spanish guidelines for management of chronic obstructive pulmonary disease (GesEPOC) 2017. Pharmacological treatment of stable phase. Arch Bronconeumol. 2017 Jun;53(6):324-35. doi: 10.1016/j.arbres.2017.03.018, PMID 28477954.
GOLD report global initiative for chronic obstructive lung disease GOLD; 2024. Available from: https://goldcopd.org/2024-gold-report/.
Aisanov Z, Avdeev S, Arkhipov V, Belevskiy A, Chuchalin A, Leshchenko I. Russian guidelines for the management of COPD: algorithm of pharmacologic treatment. Int J Chron Obstruct Pulmon Dis. 2018 Jan 8;13:183-7. doi: 10.2147/COPD.S153770, PMID 29386887.
Sliwinski P, Gorecka D, Jassem E, Pierzchala W. Polish respiratory society guidelines for chronic obstructive pulmonary disease. Pneumonol Alergol Pol. 2014;82(3):227-63. doi: 10.5603/PiAP.2014.0030, PMID 24793150.
Pleguezuelos E, Gimeno Santos E, Hernandez C, Mata MD, Palacios L, Pinera P. Recommendations on non-pharmacological treatment in chronic obstructive pulmonary disease from the spanish COPD guidelines (GesEPOC 2017). Arch Bronconeumol. 2018;54(11):568-75. doi: 10.1016/j.arbres.2018.06.001, PMID 30241689.
Zysman M, Chabot F, Housset B, Morelot Panzini C, Devillier P, Roche N. Pharmacological treatment optimisation for stable COPD: an endless story? proposals from the societe de pneumologie de langue francaise. Eur Respir J. 2017;50(4):1701250. doi: 10.1183/13993003.01250-2017, PMID 29025880.
Vukoja M, Kopitovic I, Lazic Z, Milenkovic B, Stankovic I, Zvezdin B. Diagnosis and management of chronic obstructive pulmonary disease in Serbia: an expert group position statement. Int J Chron Obstruct Pulmon Dis. 2019;14:1993-2002. doi: 10.2147/COPD.S214690, PMID 31564847.
Miravitlles M, Vogelmeier C, Roche N, Halpin D, Cardoso J, Chuchalin AG. A review of national guidelines for management of COPD in Europe. Eur Respir J. 2016;47(2):625-37. doi: 10.1183/13993003.01170-2015, PMID 26797035.
Wedzicha JA, Miravitlles M, Hurst JR, Calverley PM, Albert RK, Anzueto A. anagement of COPD exacerbations: a European respiratory society/American thoracic society guideline. Eur Respir J. 2017;49(3):1600791. doi: 10.1183/13993003.00791-2016, PMID 28298398.
Kankaanranta H, Harju T, Kilpelainen M, Mazur W, Lehto JT, Katajisto M. Diagnosis and pharmacotherapy of stable chronic obstructive pulmonary disease: the finnish guidelines. Basic Clin Pharmacol Toxicol. 2015;116(4):291-307. doi: 10.1111/bcpt.12366, PMID 25515181.
COPD medications: types benefits and side effects. Available from: https://www.healthgrades.com/right-care/copd/10-drugs-commonly-prescribed-for-copd.
Sathish MS. Pharm M. Formulation and evaluation of dry powder inhalers of fluticasone propionate for pulmonary delivery. Available from: http://repository-tnmgrmu.ac.in/20122/1/261104619senkathir.pdf.
Desai H, Dalal B. Management options in chronic obstructive pulmonary disease. Clinical Medicine Insights: Therapeutics. 2012;4. doi: 10.4137/CMT.S6563.
Gold Report; 2021. Available from: https://goldcopd.org/wp-content/uploads/2020/11/GOLD-REPORT-2021-v1.1-25Nov20_WMV.pdf.
Singh D, Agusti A, Anzueto A, Barnes PJ, Bourbeau J, Celli BR. Global strategy for the diagnosis management and prevention of chronic obstructive lung disease: the gold science committee report 2019. Eur Respir J. 2019;53(5):1900164. doi: 10.1183/13993003.00164-2019, PMID 30846476.
Vogelmeier CF, Criner GJ, Martinez FJ, Anzueto A, Barnes PJ, Bourbeau J. Global strategy for the diagnosis management and prevention of chronic obstructive lung disease 2017 report: gold executive summary. Eur Respir J. 2017;49(3):1700214. doi: 10.1183/13993003.00214-2017, PMID 28182564.
Halpin DM, Criner GJ, Papi A, Singh D, Anzueto A, Martinez FJ. Global initiative for the diagnosis, management and prevention of chronic obstructive lung disease. the 2020 gold science committee report on COVID-19 and chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2021;203(1):24-36. doi: 10.1164/rccm.202009-3533SO, PMID 33146552.
Magramane S, Papay Z, Turbucz B, Antal I. Formulation and characterization of pulmonary drug delivery systems. Acta Pharm Hung. 2019;89(2):63-83. doi: 10.33892/aph.2019.89.63-83.
Darquenne C. Aerosol deposition in health and disease. J Aerosol Med Pulm Drug Deliv. 2012;25(3):140-7. doi: 10.1089/jamp.2011.0916, PMID 22686623.
Rangaraj N, Pailla SR, Sampathi S. Insight into pulmonary drug delivery: mechanism of drug deposition to device characterization and regulatory requirements. Pulm Pharmacol Ther. 2019 Feb;54:1-21. doi: 10.1016/j.pupt.2018.11.004, PMID 30447295.
Darquenne C. Deposition mechanisms. J Aerosol Med Pulm Drug Deliv. 2020;33(4):181-5. doi: 10.1089/jamp.2020.29029.cd, PMID 32598200.
Jessamine V, Mehndiratta S, DE Rubis G, Paudel KR, Shetty S, Suares D. The application of nanoparticles as advanced drug delivery systems in attenuating COPD. Heliyon. 2024;10(3):e25393. doi: 10.1016/j.heliyon.2024.e25393, PMID 38356590.
Shetty N, Cipolla D, Park H, Zhou QT. Physical stability of dry powder inhaler formulations. Expert Opin Drug Deliv. 2020;17(1):77-96. doi: 10.1080/17425247.2020.1702643, PMID 31815554.
Vernon Parry KD. Scanning electron microscopy: an introduction. III-Vs Review. 2000;13(4):40-4. doi: 10.1016/S0961-1290(00)80006-X.
Gipsman AI, Lapinel NC, Mayer OH. Airway clearance in patients with neuromuscular disease. Paediatr Respir Rev. 2023 Sep;47:33-40. doi: 10.1016/j.prrv.2023.02.002, PMID 36894356.
Restrepo RD. Inhaled adrenergics and anticholinergics in obstructive lung disease: do they enhance mucociliary clearance. Respir Care. 2007;52(9):1159-73. PMID 17716384.
O Donnell DE, Milne KM, James MD, DE Torres JP, Neder JA. Dyspnea in COPD: new mechanistic insights and management implications. Adv Ther. 2020;37(1):41-60. doi: 10.1007/s12325-019-01128-9, PMID 31673990.
Chronic obstructive pulmonary disease (COPD) Straight to the point of care. Cleveland Clinic; 2023.
Han MK, Host MFJ. Gender and early life factors as risks for chronic obstructive pulmonary disease. Clinics in Chest Medicine. 2020;41(3):329-37. doi: 10.1016/j.ccm.2020.06.009.
Tobacco. Available from: https://www.who.int/news-room/fact-sheets/detail/tobacco.references.
Patel MP, Khangoora VS, Marik PE. A review of the pulmonary and health impacts of hookah use. Ann Am Thorac Soc. 2019;16(10):1215-9. doi: 10.1513/AnnalsATS.201902-129CME, PMID 31091965.
Clementi EA, Talusan A, Vaidyanathan S, Veerappan A, Mikhail M, Ostrofsky D. Metabolic syndrome and air pollution: a narrative review of their cardiopulmonary effects. Toxics. 2019;7(1):6. doi: 10.3390/toxics7010006, PMID 30704059.
Pirozzi C, Scholand MB. Smoking cessation and environmental hygiene. Med Clin North Am. 2012;96(4):849-67. doi: 10.1016/j.mcna.2012.04.014, PMID 22793948.
COPD causes occupations and substances. Available from: https://www.hse.gov.uk/copd/causes.htm#substances.
Teresa H. Mosbys pharmacy technician-e-book: principles and practice; 2014. p. 1136.
Brode SK, Ling SC, Chapman KR. Alpha-1 antitrypsin deficiency: a commonly overlooked cause of lung disease. CMAJ. 2012;184(12):1365-71. doi: 10.1503/cmaj.111749, PMID 22761482.
Foreman MG, Campos M, Celedon JC. Genes and chronic obstructive pulmonary disease. Med Clin North Am. 2012;96(4):699-711. doi: 10.1016/j.mcna.2012.02.006, PMID 22793939.
COPD. Causes and risk factors NHLBI, NIH, https://www.nhlbi.nih.gov/health/copd/causes.
Salvi S, Ghorpade D. COPD in never smokers. In: Encyclopedia of respiratory medicine. 2nd ed. Elsevier; 2021. p. 686-701.
Ruvuna L, Sood A. Epidemiology of chronic obstructive pulmonary disease. Clin Chest Med. 2020;41(3):315-27. doi: 10.1016/j.ccm.2020.05.002, PMID 32800187.
Maselli DJ, Bhatt SP, Anzueto A, Bowler RP, DE Meo DL, Diaz AA. Clinical epidemiology of COPD: insights from 10 y of the copdgene study. Chest. 2019;156(2):228-38. doi: 10.1016/j.chest.2019.04.135, PMID 31154041.
Sarath Chandran C, Raj A, Shahin Muhammed TK. Probing the cellular and molecular mechanisms underlying in the pathogenesis of chronic obstructive pulmonary disease. Target Cell Signal Pathw Lung Dis. 2021;7:147-62.
Herr C, Lungarella G, Puttur F. Mechanisms of virus-induced airway immunity dysfunction in the pathogenesis of COPD disease progression and exacerbation. Front Immunol. 2020 Jun 16;11:1205. doi: 10.3389/fimmu.2020.01205.
Bordi L, Vulcano A, Sberna G, Nonis M, Giacomini P, Maggi F. Co-circulation of SARS-CoV-2 and other respiratory pathogens in upper and lower respiratory tracts during influenza season 2022-2023 in lazio region. Microorganisms. 2023;11(9):2239. doi: 10.3390/microorganisms11092239, PMID 37764083.
Rodriguez Roisin R, Drakulovic M, Rodriguez DA, Roca J, Barbera JA, Wagner PD. Ventilation perfusion imbalance and chronic obstructive pulmonary disease staging severity. J Appl Physiol 1985. 2009;106(6):1902-8. doi: 10.1152/japplphysiol.00085.2009, PMID 19372303.
Elbehairy AF, Ciavaglia CE, Webb KA, Guenette JA, Jensen D, Mourad SM. Pulmonary gas exchange abnormalities in mild chronic obstructive pulmonary disease implications for dyspnea and exercise intolerance. Am J Respir Crit Care Med. 2015;191(12):1384-94. doi: 10.1164/rccm.201501-0157OC, PMID 25826478.
Colak Y, Nordestgaard BG, Vestbo J, Lange P, Afzal S. Prognostic significance of chronic respiratory symptoms in individuals with normal spirometry. Eur Respir J. 2019;54(3). doi: 10.1183/13993003.00734-2019.
Quanjer PH, Stanojevic S, Cole TJ, Baur X, Hall GL, Culver BH. Multi-ethnic reference values for spirometry for the 3-95 y age range: the global lung function 2012 equations. Eur Respir J. 2012;40(6):1324-43. doi: 10.1183/09031936.00080312, PMID 22743675.
Walker PP, Calverley PM. The volumetric response to bronchodilators in stable chronic obstructive pulmonary disease. COPD. 2008;5(3):147-52. doi: 10.1080/15412550802092928, PMID 18568838.
Calverley PM, Albert P, Walker PP. Bronchodilator reversibility in chronic obstructive pulmonary disease: use and limitations. Lancet Respir Med. 2013;1(7):564-73. doi: 10.1016/S2213-2600(13)70086-9, PMID 24461617.
Enright PL, Beck KC, Sherrill DL. Repeatability of spirometry in 18,000 adult patients. Am J Respir Crit Care Med. 2004;169(2):235-8. doi: 10.1164/rccm.200204-347OC, PMID 14604836.
Fortis S, Eberlein M, Georgopoulos D, Comellas AP. Predictive value of prebronchodilator and postbronchodilator spirometry for COPD features and outcomes. BMJ Open Respir Res. 2017;4(1):e000213. doi: 10.1136/bmjresp-2017-000213, PMID 29435342.
Buhr RG, Barjaktarevic IZ, Quibrera PM, Bateman LA, Bleecker ER, Couper DJ. Reversible airflow obstruction predicts future chronic obstructive pulmonary disease development in the spiromics cohort: an observational cohort study. Am J Respir Crit Care Med. 2022;206(5):554-62. doi: 10.1164/rccm.202201-0094OC, PMID 35549640.
Oba Y, Keeney E, Ghatehorde N, Dias S. Dual combination therapy versus long-acting bronchodilators alone for chronic obstructive pulmonary disease (COPD): a systematic review and network meta-analysis. Cochrane Database Syst Rev. 2018;12(12):CD012620. doi: 10.1002/14651858.CD012620.pub2, PMID 30521694.
Maltais F, Bjermer L, Kerwin EM, Jones PW, Watkins ML, Tombs L. Efficacy of umeclidinium/vilanterol versus umeclidinium and salmeterol monotherapies in symptomatic patients with COPD not receiving inhaled corticosteroids: the Emax randomised trial. Respir Res. 2019;20(1):238. doi: 10.1186/s12931-019-1193-9, PMID 31666084.
Lange P, Marott JL, Vestbo J, Olsen KR, Ingebrigtsen TS, Dahl M. Prediction of the clinical course of chronic obstructive pulmonary disease using the new gold classification. Am J Respir Crit Care Med. 2012;186(10):975-81. doi: 10.1164/rccm.201207-1299OC.
Lipson DA, Barnhart F, Brealey N, Brooks J, Criner GJ, Day NC. Once daily single inhaler triple versus dual therapy in patients with COPD. N Engl J Med. 2018;378(18):1671-80. doi: 10.1056/NEJMoa1713901, PMID 29668352.
Rabe KF, Martinez FJ, Ferguson GT, Wang C, Singh D, Wedzicha JA. Triple inhaled therapy at two glucocorticoid doses in moderate to very severe COPD. N Engl J Med. 2020;383(1):35-48. doi: 10.1056/NEJMoa1916046, PMID 32579807.
W H Kocks J, Wouters H, Bosnic Anticevich S, Van Cooten J, Correia DE Sousa J, Cvetkovski B. Factors associated with health status and exacerbations in COPD maintenance therapy with dry powder inhalers. NPJ Prim Care Respir Med. 2022;32(1):18. doi: 10.1038/s41533-022-00282-y, PMID 35618739.
Vestbo J, Anderson J, Brook RD, Calverley PM, Celli BR, Crim C. The study to understand mortality and morbidity in copd (summit) study protocol. Eur Respir J. 2013;41(5):1017-22. doi: 10.1183/09031936.00087312, PMID 23018908.
Calverley PM, Anderson JA, Celli B, Ferguson GT, Jenkins C, Jones PW. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med. 2007;356(8):775-89. doi: 10.1056/NEJMoa063070, PMID 17314337.
Rabe KF, Martinez FJ, Ferguson GT, Wang C, Singh D, Wedzicha JA. Triple inhaled therapy at two glucocorticoid doses in moderate to very severe COPD. N Engl J Med. 2020;383(1):35-48. doi: 10.1056/NEJMoa1916046, PMID 32579807.
Lipson DA, Barnhart F, Brealey N, Brooks J, Criner GJ, Day NC. Once daily single inhaler triple versus dual therapy in patients with COPD. N Engl J Med. 2018;378(18):1671-80. doi: 10.1056/NEJMoa1713901, PMID 29668352.
Chrystyn H, Mulley BA, Peake MD. Dose-response relation to oral theophylline in severe chronic obstructive airways disease. BMJ. 1988;297(6662):1506-10. doi: 10.1136/bmj.297.6662.1506, PMID 3147048.
Gross NJ, Petty TL, Friedman M, Skorodin MS, Silvers GW, Donohue JF. Dose response to ipratropium as a nebulized solution in patients with chronic obstructive pulmonary disease a three center study. Am Rev Respir Dis. 1989;139(5):1188-91. doi: 10.1164/ajrccm/139.5.1188, PMID 2523681.
Higgins BG, Powell RM, Cooper S, Tattersfield AE. Effect of salbutamol and ipratropium bromide on airway calibre and bronchial reactivity in asthma and chronic bronchitis PubMed. Eur Respir J. 1991;4(4):415-20. PMID 1830277.
Donohue JF, Anzueto A, Brooks J, Mehta R, Kalberg C, Crater G. A randomized double blind dose ranging study of the novel LAMA GSK573719 in patients with COPD. Respir Med. 2012;106(7):970-9. doi: 10.1016/j.rmed.2012.03.012, PMID 22498110.
Donohue JF, Kalberg C, Shah P, Beerahee M, Mehta R, Gunawan R. Dose response of umeclidinium administered once or twice daily in patients with COPD: a pooled analysis of two randomized double blind placebo controlled studies. J Clin Pharmacol. 2014;54(11):1214-20. doi: 10.1002/jcph.340, PMID 24895108.
Chowdhury BA, Seymour SM, Michele TM, Durmowicz AG, Liu D, Rosebraugh CJ. The risks and benefits of indacaterol the FDA’s review. N Engl J Med. 2011;365(24):2247-9. doi: 10.1056/NEJMp1109621, PMID 22168640.
O Donnell DE, Sciurba F, Celli B, Mahler DA, Webb KA, Kalberg CJ. Effect of fluticasone propionate/salmeterol on lung hyperinflation and exercise endurance in COPD. Chest. 2006;130(3):647-56. doi: 10.1378/chest.130.3.647, PMID 16963658.
Kempsford R, Norris V, Siederer S. Vilanterol trifenatate a novel inhaled long-acting beta2 adrenoceptor agonist is well tolerated in healthy subjects and demonstrates prolonged bronchodilation in subjects with asthma and COPD. Pulm Pharmacol Ther. 2013;26(2):256-64. doi: 10.1016/j.pupt.2012.12.001, PMID 23232038.
Koch A, Pizzichini E, Hamilton A, Hart L, Korducki L, DE Salvo MC. Lung function efficacy and symptomatic benefit of olodaterol once daily delivered via respimat® versus placebo and formoterol twice daily in patients with gold 2-4 COPD: results from two replicate 48-week studies. Int J Chron Obstruct Pulmon Dis. 2014 Jul 5;9:697-714. doi: 10.2147/COPD.S62502, PMID 25045258.
Cazzola M, Rogliani P, Ruggeri P, Segreti A, Proietto A, Picciolo S. Chronic treatment with indacaterol and airway response to salbutamol in stable COPD. Respir Med. 2013;107(6):848-53. doi: 10.1016/j.rmed.2013.02.008, PMID 23490225.
Sestini P, Renzoni E, Robinson S. Short-acting beta2 agonists for stable chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2002 Jul 22:2002(3):CD001495. doi: 10.1002/14651858.CD001495.
Donohue JF, Anzueto A, Brooks J, Mehta R, Kalberg C, Crater G. A randomized, double-blind dose-ranging study of the novel LAMA GSK573719 in patients with COPD. Respir Med. 2012;106(7):970-9. doi: 10.1016/j.rmed.2012.03.012, PMID 22498110.
O Driscoll BR, Kay EA, Taylor RJ, Weatherby H, Chetty MC, Bernstein A. A long-term prospective assessment of home nebulizer treatment. Respir Med. 1992;86(4):317-25. doi: 10.1016/s0954-6111(06)80031-4, PMID 1448587.
Jenkins SC, Heaton RW, Fulton TJ, Moxham J. Comparison of domiciliary nebulized salbutamol and salbutamol from a metered dose inhaler in stable chronic airflow limitation. Chest. 1987;91(6):804-7. doi: 10.1378/chest.91.6.804, PMID 3556051.
Chowdhury BA, Seymour SM, Michele TM, Durmowicz AG, Liu D, Rosebraugh CJ. The risks and benefits of indacaterol the FDA’s review. N Engl J Med. 2011;365(24):2247-9. doi: 10.1056/NEJMp1109621, PMID 22168640.
Donohue JF, Anzueto A, Brooks J, Mehta R, Kalberg C, Crater G. A randomized double-blind dose ranging study of the novel LAMA GSK573719 in patients with COPD. Respir Med. 2012;106(7):970-9. doi: 10.1016/j.rmed.2012.03.012, PMID 22498110.
Vathenen AS, Britton JR, Ebden P, Cookson JB, Wharrad HJ, Tattersfield AE. High-dose inhaled albuterol in severe chronic airflow limitation. Am Rev Respir Dis. 1988;138(4):850-5. doi: 10.1164/ajrccm/138.4.850, PMID 2462383.
Melani AS. Long-acting muscarinic antagonists. Expert Rev Clin Pharmacol. 2015;8(4):479-501. doi: 10.1586/17512433.2015.1058154, PMID 26109098.
Decramer ML, Chapman KR, Dahl R, Frith P, Devouassoux G, Fritscher C. Once daily indacaterol versus tiotropium for patients with severe chronic obstructive pulmonary disease (invigorate): a randomised blinded, parallel group study. Lancet Respir Med. 2013;1(7):524-33. doi: 10.1016/S2213-2600(13)70158-9, PMID 24461613.
Vogelmeier C, Hederer B, Glaab T, Schmidt H, Rutten Van Molken MP, Beeh KM. Tiotropium versus salmeterol for the prevention of exacerbations of COPD. N Engl J Med. 2011;364(12):1093-103. doi: 10.1056/NEJMoa1008378, PMID 21428765.
Casaburi R, Kukafka D, Cooper CB, Witek TJ, Kesten S. Improvement in exercise tolerance with the combination of tiotropium and pulmonary rehabilitation in patients with COPD. Chest. 2005;127(3):809-17. doi: 10.1378/chest.127.3.809, PMID 15764761.
Calzetta L, Ritondo BL, Zappa MC, Manzetti GM, Perduno A, Shute J. The impact of long acting muscarinic antagonists on mucus hypersecretion and cough in chronic obstructive pulmonary disease: a systematic review. Eur Respir Rev. 2022;31(164):210196. doi: 10.1183/16000617.0196-2021, PMID 35508331.
Karner C, Chong J, Poole P. Tiotropium versus placebo for chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2014;11(7):CD009285. doi: 10.1002/14651858.CD009285.pub3.
Appleton S, Jones T, Poole P, Pilotto L, Adams R, Lasserson TJ. Ipratropium bromide versus long-acting beta-2 agonists for stable chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2006;2006(3):CD006101. doi: 10.1002/14651858.CD006101, PMID 16856113.
Suissa S, Dell Aniello S, Ernst P. Comparative effectiveness and safety of LABA-LAMA vs LABA-ICS treatment of COPD in real-world clinical practice. Chest. 2019;155(6):1158-65. doi: 10.1016/j.chest.2019.03.005, PMID 30922950.
Boardman C, Chachi L, Gavrila A, Keenan CR, Perry MM, Xia YC. Mechanisms of glucocorticoid action and insensitivity in airways disease. Pulm Pharmacol Ther. 2014;29(2):129-43. doi: 10.1016/j.pupt.2014.08.008, PMID 25218650.
Barnes PJ. New anti-inflammatory targets for chronic obstructive pulmonary disease. Nat Rev Drug Discov. 2013;12(7):543-59. doi: 10.1038/nrd4025, PMID 23977698.
Wedzicha JA, Banerji D, Chapman KR, Vestbo J, Roche N, Ayers RT. Indacaterol glycopyrronium versus salmeterol fluticasone for COPD. N Engl J Med. 2016;374(23):2222-34. doi: 10.1056/NEJMoa1516385, PMID 27181606.
Lipson DA, Barnhart F, Brealey N, Brooks J, Criner GJ, Day NC. Once daily single inhaler triple versus dual therapy in patients with COPD. N Engl J Med. 2018;378(18):1671-80. doi: 10.1056/NEJMoa1713901, PMID 29668352.
Sonnex K, Alleemudder H, Knaggs R. Impact of smoking status on the efficacy of inhaled corticosteroids in chronic obstructive pulmonary disease: a systematic review. BMJ Open. 2020;10(4):e037509. doi: 10.1136/BMJOPEN-2020-037509, PMID 32300001.
Manson SC, Brown RE, Cerulli A, Vidaurre CF. The cumulative burden of oral corticosteroid side effects and the economic implications of steroid use. Respir Med. 2009;103(7):975-94. doi: 10.1016/j.rmed.2009.01.003, PMID 19372037.
Walters JA, Tan DJ, White CJ, Gibson PG, Wood Baker R, Walters EH. Systemic corticosteroids for acute exacerbations of chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2014;2014(9):CD001288. doi: 10.1002/14651858.CD001288.pub4, PMID 25178099.
Rice K, Rubins J, Lebahn F, Parenti C, Duane P, Kuskowski M. Withdrawal of chronic systemic corticosteroids in patients with COPD. Am J Respir Crit Care Med. 2000;162(1):174-8. doi: 10.1164/ajrccm.162.1.9909066.
Uzun S, Djamin RS, Kluytmans JA, Mulder PG, Vant Veer NE, Ermens AA. Azithromycin maintenance treatment in patients with frequent exacerbations of chronic obstructive pulmonary disease (Columbus): a randomised double-blind placebo controlled trial. Lancet Respir Med. 2014;2(5):361-8. doi: 10.1016/S2213-2600(14)70019-0, PMID 24746000.
Rabe KF. Update on roflumilast a phosphodiesterase 4 inhibitor for the treatment of chronic obstructive pulmonary disease. Br J Pharmacol. 2011;163(1):53-67. doi: 10.1111/j.1476-5381.2011.01218.x, PMID 21232047.
Calverley PM, Rabe KF, Goehring UM, Kristiansen S, Fabbri LM, Martinez FJ. Roflumilast in symptomatic chronic obstructive pulmonary disease: two randomised clinical trials. Lancet. 2009;374(9691):685-94. doi: 10.1016/S0140-6736(09)61255-1, PMID 19716960.
Martinez FJ, Calverley PM, Goehring UM, Brose M, Fabbri LM, Rabe KF. Effect of roflumilast on exacerbations in patients with severe chronic obstructive pulmonary disease uncontrolled by combination therapy (REACT): a multicentre randomised controlled trial. Lancet. 2015;385(9971):857-66. doi: 10.1016/S0140-6736(14)62410-7, PMID 25684586.
Fabbri LM, Calverley PM, Izquierdo Alonso JL, Bundschuh DS, Brose M, Martinez FJ. Roflumilast in moderate to severe chronic obstructive pulmonary disease treated with longacting bronchodilators: two randomised clinical trials. Lancet. 2009;374(9691):695-703. doi: 10.1016/S0140-6736(09)61252-6, PMID 19716961.
Rabe KF, Calverley PM, Martinez FJ, Fabbri LM. Effect of roflumilast in patients with severe COPD and a history of hospitalisation. Eur Respir J. 2017;50(1):1700158. doi: 10.1183/13993003.00158-2017, PMID 28679611.
Albert RK, Connett J, Bailey WC, Casaburi R, Cooper JA, Criner GJ. Azithromycin for prevention of exacerbations of COPD. N Engl J Med. 2011;365(8):689-98. doi: 10.1056/NEJMoa1104623, PMID 21864166.
Nannini LJ, Lasserson TJ, Poole P. Combined corticosteroid and long-acting beta(2) agonist in one inhaler versus long-acting beta(2) agonists for chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2013 Aug 30;2013(8):CD006829. doi: 10.1002/14651858.CD006829.pub2, PMID 22972099.
Nannini LJ, Poole P, Milan SJ, Kesterton A. Combined corticosteroid and long-acting beta(2) agonist in one inhaler versus inhaled corticosteroids alone for chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2013;8:CD006826. doi: 10.1002/14651858.CD006826.pub2, PMID 23990350.
Vestbo J, Anderson JA, Brook RD, Calverley PM, Celli BR, Crim C. Fluticasone furoate and vilanterol and survival in chronic obstructive pulmonary disease with heightened cardiovascular risk (SUMMIT): a double-blind randomised controlled trial. Lancet. 2016;387(10030):1817-26. doi: 10.1016/S0140-6736(16)30069-1, PMID 27203508.
Calverley PM, Anderson JA, Celli B, Ferguson GT, Jenkins C, Jones PW. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med. 2007;356(8):775-89. doi: 10.1056/NEJMoa063070, PMID 17314337.
Vestbo J, Leather D, Diar Bakerly N, New J, Gibson JM, MC Corkindale S. Effectiveness of fluticasone furoate vilanterol for COPD in clinical practice. N Engl J Med. 2016;375(13):1253-60. doi: 10.1056/NEJMoa1608033, PMID 27593504.
Brusselle G, Price D, Gruffydd Jones K. The inevitable drift to triple therapy in COPD: an analysis of prescribing pathways in the UK. Int J COPD. 2015 Oct 15;10:2207-17. doi: 10.2147/COPD.S91694.
Singh D, Brooks J, Hagan G, Cahn A, O Connor BJ. Superiority of triple therapy with salmeterol/fluticasone propionate and tiotropium bromide versus individual components in moderate to severe COPD. Thorax. 2008;63(7):592-8. doi: 10.1136/thx.2007.087213, PMID 18245142.
Welte T, Miravitlles M, Hernandez P, Eriksson G, Peterson S, Polanowski T. Efficacy and tolerability of budesonide/formoterol added to tiotropium in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2009;180(8):741-50. doi: 10.1164/rccm.200904-0492OC, PMID 19644045.
Singh D, Papi A, Corradi M, Pavlisova I, Montagna I, Francisco C. Single inhaler triple therapy versus inhaled corticosteroid plus long-acting β2-agonist therapy for chronic obstructive pulmonary disease (TRILOGY): a double-blind parallel group randomised controlled trial. Lancet. 2016;388(10048):963-73. doi: 10.1016/S0140-6736(16)31354-X, PMID 27598678.
Siler TM, Kerwin E, Singletary K, Brooks J, Church A. Efficacy and safety of umeclidinium added to fluticasone propionate/salmeterol in patients with COPD: results of two randomized double blind studies. COPD. 2016;13(1):1-10. doi: 10.3109/15412555.2015.1034256, PMID 26451734.
Lipson DA, Barnacle H, Birk R, Brealey N, Locantore N, Lomas DA. FULFIL trial: once daily triple therapy for patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2017;196(4):438-46. doi: 10.1164/rccm.201703-0449OC, PMID 28375647.
Frith PA, Thompson PJ, Ratnavadivel R, Chang CL, Bremner P, Day P. Glycopyrronium once daily significantly improves lung function and health status when combined with salmeterol/fluticasone in patients with COPD: the GLISTEN study a randomised controlled trial. Thorax. 2015;70(6):519-27. doi: 10.1136/thoraxjnl-2014-206670, PMID 25841237.
Hanania NA, Crater GD, Morris AN, Emmett AH, O Dell DM, Niewoehner DE. Benefits of adding fluticasone propionate/salmeterol to tiotropium in moderate to severe COPD. Respir Med. 2012;106(1):91-101. doi: 10.1016/j.rmed.2011.09.002, PMID 22040533.
Jung KS, Park HY, Park SY, Kim SK, Kim YK, Shim JJ. Comparison of tiotropium plus fluticasone propionate/salmeterol with tiotropium in COPD: a randomized controlled study. Respir Med. 2012;106(3):382-9. doi: 10.1016/j.rmed.2011.09.004, PMID 21975275.
Vestbo J, Papi A, Corradi M, Blazhko V, Montagna I, Francisco C. Single inhaler extrafine triple therapy versus long-acting muscarinic antagonist therapy for chronic obstructive pulmonary disease (Trinity): a double-blind parallel-group randomised controlled trial. Lancet. 2017;389(10082):1919-29. doi: 10.1016/S0140-6736(17)30188-5, PMID 28385353.
Lipson DA, Barnhart F, Brealey N, Brooks J, Criner GJ, Day NC. Once daily single inhaler triple versus dual therapy in patients with COPD. N Engl J Med. 2018;378(18):1671-80. doi: 10.1056/NEJMoa1713901, PMID 29668352.
Papi A, Vestbo J, Fabbri L, Corradi M, Prunier H, Cohuet G. Extrafine inhaled triple therapy versus dual bronchodilator therapy in chronic obstructive pulmonary disease (Tribute): a double-blind parallel group randomised controlled trial. Lancet. 2018;391(10125):1076-84. doi: 10.1016/S0140-6736(18)30206-X, PMID 29429593.
Bardsley S, Criner GJ, Halpin DM, Han MK, Hanania NA, Hill D. Single inhaler triple therapy fluticasone furoate/umeclidinium/vilanterol versus dual therapy in current and former smokers with COPD: impact trial post hoc analysis. Respir Med. 2022 Dec;205:107040. doi: 10.1016/j.rmed.2022.107040, PMID 36470149.
Vestbo J, Fabbri L, Papi A, Petruzzelli S, Scuri M, Guasconi A. Inhaled corticosteroid containing combinations and mortality in COPD. Eur Respir J. 2018;52(6):1801230. doi: 10.1183/13993003.01230-2018, PMID 30209195.
Francis RS, Spicer CC. Chemotherapy in chronic bronchitis. Influence of daily penicillin and tetracycline on exacerbations and their cost. Br Med J. 1960;1(5169):297-303. doi: 10.1136/bmj.1.5169.297, PMID 13824401.
Francis RS, May JR, Spicer CC. Chemotherapy of bronchitis influence of penicillin and tetracycline administered daily or intermittently for exacerbations a report to the research committee of the British Tuberculosis Association by its bronchitis subcommittee. Br Med J. 1961;2(5258):979-85. doi: 10.1136/bmj.2.5258.979, PMID 13894512.
Johnston RN, MC Neill RS, Smith DH, Dempster MB, Nairn JR, Purvis MS. Five-year winter chemoprophylaxis for chronic bronchitis. Br Med J. 1969;4(5678):265-9. doi: 10.1136/bmj.4.5678.265, PMID 4899454.
NI W, Shao X, Cai X, Wei C, Cui J, Wang R. Prophylactic use of macrolide antibiotics for the prevention of chronic obstructive pulmonary disease exacerbation: a meta-analysis. Plos One. 2015;10(3):e0121257. doi: 10.1371/journal.pone.0121257, PMID 25812085.
Herath SC, Poole P. Prophylactic antibiotic therapy for chronic obstructive pulmonary disease (COPD). Cochrane Database Syst Rev. 2018 Oct 30;10(10):CD009764. doi: 10.1002/14651858.CD009764.pub3.
Uzun S, Djamin RS, Kluytmans JA, Mulder PG, Vant Veer NE, Ermens AA. Azithromycin maintenance treatment in patients with frequent exacerbations of chronic obstructive pulmonary disease (COLUMBUS): a randomised double-blind placebo controlled trial. Lancet Respir Med. 2014;2(5):361-8. doi: 10.1016/S2213-2600(14)70019-0, PMID 24746000.
Seemungal TA, Wilkinson TM, Hurst JR, Perera WR, Sapsford RJ, Wedzicha JA. Long-term erythromycin therapy is associated with decreased chronic obstructive pulmonary disease exacerbations. Am J Respir Crit Care Med. 2008;178(11):1139-47. doi: 10.1164/rccm.200801-145OC, PMID 18723437.
Albert RK, Connett J, Bailey WC, Casaburi R, Cooper JA, Criner GJ. Azithromycin for prevention of exacerbations of COPD. N Engl J Med. 2011;365(8):689-98. doi: 10.1056/NEJMoa1104623, PMID 21864166.
Han MK, Tayob N, Murray S, Dransfield MT, Washko G, Scanlon PD. Predictors of chronic obstructive pulmonary disease exacerbation reduction in response to daily azithromycin therapy. Am J Respir Crit Care Med. 2014;189(12):1503-8. doi: 10.1164/rccm.201402-0207OC, PMID 24779680.
Sethi S, Jones PW, Theron MS, Miravitlles M, Rubinstein E, Wedzicha JA. Pulsed moxifloxacin for the prevention of exacerbations of chronic obstructive pulmonary disease: a randomized controlled trial. Respir Res. 2010;11(1):10. doi: 10.1186/1465-9921-11-10, PMID 20109213.
Allinson JP, Vlies BH, Brill SE, Law M, Burnside G, Finney LJ. A double blind randomized placebo-controlled trial of long-term doxycycline therapy on exacerbation rate in patients with stable chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2023;208(5):549-58. doi: 10.1164/rccm.202212-2287OC, PMID 37450935.
Rogliani P, Matera MG, Page C, Puxeddu E, Cazzola M, Calzetta L. Efficacy and safety profile of mucolytic/antioxidant agents in chronic obstructive pulmonary disease: a comparative analysis across erdosteine carbocysteine and N-acetylcysteine. Respir Res. 2019;20(1):104. doi: 10.1186/s12931-019-1078-y, PMID 31133026.
Dal Negro RW, Wedzicha JA, Iversen M, Fontana G, Page C, Cicero AF. Effect of erdosteine on the rate and duration of COPD exacerbations: the restore study. Eur Respir J. 2017;50(4):1700711. doi: 10.1183/13993003.00711-2017, PMID 29025888.
Poole P, Chong J, Cates CJ. Mucolytic agents versus placebo for chronic bronchitis or chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2015 Jul 29;7:CD001287. doi: 10.1002/14651858.CD001287.pub5, PMID 26222376.
Cazzola M, Calzetta L, Page C, Jardim J, Chuchalin AG, Rogliani P. Influence of N-acetylcysteine on chronic bronchitis or COPD exacerbations: a meta-analysis. Eur Respir Rev. 2015;24(137):451-61. doi: 10.1183/16000617.00002215, PMID 26324807.
Poole P, Sathananthan K, Fortescue R. Mucolytic agents versus placebo for chronic bronchitis or chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2019 May 20;5(5):CD001287. doi: 10.1002/14651858.CD001287.pub6, PMID 31107966.
Effing TW, Vercoulen JH, Bourbeau J, Trappenburg J, Lenferink A, Cafarella P. Definition of a COPD self-management intervention: international expert group consensus. Eur Respir J. 2016;48(1):46-54. doi: 10.1183/13993003.00025-2016, PMID 27076595.
Schrijver J, Lenferink A, Brusse Keizer M, Zwerink M, Van Der Valk PD, Van Der Palen J. Self-management interventions for people with chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2022;1(1):CD002990. doi: 10.1002/14651858.CD002990.pub4, PMID 35001366.
Rose L, Istanboulian L, Carriere L, Thomas A, Lee HB, Rezaie S. Program of integrated care for patients with chronic obstructive pulmonary disease and multiple comorbidities (pic copd+): a randomised controlled trial. Eur Respir J. 2018;51(1):1701567. doi: 10.1183/13993003.01567-2017, PMID 29326330.
Kessler R, Casan Clara P, Koehler D, Tognella S, Viejo JL, Dal Negro RW. Comet: a multicomponent home-based disease management programme versus routine care in severe COPD. Eur Respir J. 2018;51(1):1701612. doi: 10.1183/13993003.01612-2017, PMID 29326333.
Aboumatar H, Naqibuddin M, Chung S, Chaudhry H, Kim SW, Saunders J. Effect of a hospital initiated program combining transitional care and long term self-management support on outcomes of patients hospitalized with chronic obstructive pulmonary disease: a randomized clinical trial. JAMA. 2019;322(14):1371-80. doi: 10.1001/jama.2019.11982, PMID 31593271.
Benzo R, Vickers K, Novotny PJ, Tucker S, Hoult J, Neuenfeldt P. Health coaching and chronic obstructive pulmonary disease rehospitalization. a randomized study. Am J Respir Crit Care Med. 2016;194(6):672-80. doi: 10.1164/rccm.201512-2503OC, PMID 26953637.
Benzo R, MC Evoy C. Effect of health coaching delivered by a respiratory therapist or nurse on self-management abilities in severe copd: analysis of a large randomized study. Respir Care. 2019;64(9):1065-72. doi: 10.4187/respcare.05927, PMID 30914491.
Poot CC, Meijer E, Kruis AL, Smidt N, Chavannes NH, Honkoop PJ. Integrated disease management interventions for patients with chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2021;9(9):CD009437. doi: 10.1002/14651858.CD009437.pub3, PMID 34495549.
Kruis AL, Boland MR, Assendelft WJ, Gussekloo J, Tsiachristas A, Stijnen T. Effectiveness of integrated disease management for primary care chronic obstructive pulmonary disease patients: results of cluster randomised trial. BMJ. 2014;349:g5392. doi: 10.1136/bmj.g5392, PMID 25209620.
Cartwright M, Hirani SP, Rixon L. Effect of telehealth on quality of life and psychological outcomes over 12 mo (Whole systems demonstrator telehealth questionnaire study): nested study of patient-reported outcomes in a pragmatic cluster randomised controlled trial. BMJ. 2013 Feb 26;346:f653. doi: 10.1136/bmj.f653.
Gregersen TL, Green A, Frausing E, Ringbæk T, Brondum E, Suppli Ulrik C. Do telemedical interventions improve quality of life in patients with COPD? A systematic review. Int J Chron Obstruct Pulmon Dis. 2016 Apr 21;11:809-22. doi: 10.2147/COPD.S96079, PMID 27143872.
Pitta F, Troosters T, Spruit MA, Probst VS, Decramer M, Gosselink R. Characteristics of physical activities in daily life in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2005;171(9):972-7. doi: 10.1164/rccm.200407-855OC, PMID 15665324.
Yohannes AM, Baldwin RC, Connolly M. Mortality predictors in disabling chronic obstructive pulmonary disease in old age. Age Ageing. 2002;31(2):137-40. doi: 10.1093/ageing/31.2.137, PMID 11937477.
Garcia Aymerich J, Lange P, Benet M, Schnohr P, Anto JM. Regular physical activity reduces hospital admission and mortality in chronic obstructive pulmonary disease: a population-based cohort study. Thorax. 2006;61(9):772-8. doi: 10.1136/thx.2006.060145, PMID 16738033.
Watz H, Pitta F, Rochester CL, Garcia Aymerich J, ZU Wallack R, Troosters T. An official European Respiratory Society statement on physical activity in COPD. Eur Respir J. 2014;44(6):1521-37. doi: 10.1183/09031936.00046814, PMID 25359358.
Mantoani LC, Rubio N, Mckinstry B, Mac Nee W, Rabinovich RA. Interventions to modify physical activity in patients with COPD: a systematic review. Eur Respir J. 2016;48(1):69-81. doi: 10.1183/13993003.01744-2015, PMID 27103381.
Robinson SA, Shimada SL, Quigley KS, Moy ML. A web-based physical activity intervention benefits persons with low self-efficacy in COPD: results from a randomized controlled trial. J Behav Med. 2019;42(6):1082-90. doi: 10.1007/s10865-019-00042-3, PMID 30980223.
Spielmanns M, Gloeckl R, Jarosch I, Leitl D, Schneeberger T, Boeselt T. Using a smartphone application maintains physical activity following pulmonary rehabilitation in patients with COPD: a randomised controlled trial. Thorax. 2023;78(5):442-50. doi: 10.1136/thoraxjnl-2021-218338, PMID 35450945.
Nguyen HQ, Moy ML, Liu IA, Fan VS, Gould MK, Desai SA. Effect of physical activity coaching on acute care and survival among patients with chronic obstructive pulmonary disease: a pragmatic randomized clinical trial. JAMA Netw Open. 2019;2(8):e199657. doi: 10.1001/jamanetworkopen.2019.9657, PMID 31418811.
Wan ES, Kantorowski A, Polak M, Kadri R, Richardson CR, Gagnon DR. Long-term effects of web-based pedometer mediated intervention on COPD exacerbations. Respir Med. 2020;162:105878. doi: 10.1016/j.rmed.2020.105878, PMID 32056676.
Yang Y, Wei L, Wang S, KE L, Zhao H, Mao J. The effects of pursed lip breathing combined with diaphragmatic breathing on pulmonary function and exercise capacity in patients with COPD: a systematic review and meta-analysis. Physiother Theor Pract. 2022;38(7):847-57. doi: 10.1080/09593985.2020.1805834, PMID 32808571.
Lahham A, MC Donald CF, Holland AE. Exercise training alone or with the addition of activity counseling improves physical activity levels in COPD: a systematic review and meta-analysis of randomized controlled trials. Int J Chron Obstruct Pulmon Dis. 2016 Dec 8;11:3121-36. doi: 10.2147/COPD.S121263, PMID 27994451.
Ortega F, Toral J, Cejudo P, Villagomez R, Sanchez H, Castillo J. Comparison of effects of strength and endurance training in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2002;166(5):669-74. doi: 10.1164/rccm.2107081, PMID 12204863.
Horowitz MB, Littenberg B, Mahler DA. Dyspnea ratings for prescribing exercise intensity in patients with COPD. Chest. 1996;109(5):1169-75. doi: 10.1378/chest.109.5.1169, PMID 8625662.
Garber CE, Blissmer B, Deschenes MR, Franklin BA, Lamonte MJ, Lee IM. American college of Sports Medicine position stand quantity and quality of exercise for developing and maintaining cardiorespiratory musculoskeletal and neuromotor fitness in apparently healthy adults: guidance for prescribing exercise. Med Sci Sports Exerc. 2011;43(7):1334-59. doi: 10.1249/MSS.0b013e318213fefb, PMID 21694556.
Vogiatzis I, Nanas S, Roussos C. Interval training as an alternative modality to continuous exercise in patients with COPD. Eur Respir J. 2002;20(1):12-9. doi: 10.1183/09031936.02.01152001, PMID 12166558.
Puhan MA, Busching G, Schunemann HJ, Van Oort E, Zaugg C, Frey M. Interval versus continuous high-intensity exercise in chronic obstructive pulmonary disease: a randomized trial. Ann Intern Med. 2006;145(11):816-25. doi: 10.7326/0003-4819-145-11-200612050-00006, PMID 17146066.
Liu X, FU C, HU W, Hao S, Xie L, WU X. The effect of Tai Chi on the pulmonary rehabilitation of chronic obstructive pulmonary disease: a systematic review and meta-analysis. Ann Palliat Med. 2021;10(4):3763-82. doi: 10.21037/apm-20-940, PMID 33894710.
Ramirez Venegas A, Ward J, Lentine T, Mahler DA. Salmeterol reduces dyspnea and improves lung function in patients with COPD. Chest. 1997;112(2):336-40. doi: 10.1378/chest.112.2.336, PMID 9266866.
Bernard S, Whittom F, Leblanc P, Jobin J, Belleau R, Berube C. Aerobic and strength training in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 1999;159(3):896-901. doi: 10.1164/ajrccm.159.3.9807034, PMID 10051269.
Cardim AB, Marinho PE, Nascimento JF, Fuzari HK, Dornelas DE Andrade A. Does whole-body vibration improve the functional exercise capacity of subjects with COPD? A meta-analysis. Respir Care. 2016;61(11):1552-9. doi: 10.4187/respcare.04763, PMID 27651524.
Velloso M, DO Nascimento NH, Gazzotti MR, Jardim JR. Evaluation of effects of shoulder girdle training on strength and performance of activities of daily living in patients with chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis. 2013;8:187-92. doi: 10.2147/COPD.S36606, PMID 23589685.
Beaumont M, Forget P, Couturaud F, Reychler G. Effects of inspiratory muscle training in COPD patients: a systematic review and meta-analysis. Clin Respir J. 2018;12(7):2178-88. doi: 10.1111/crj.12905, PMID 29665262.
Beaumont M, Mialon P, LE Ber C, LE Mevel P, Peran L, Meurisse O. Effects of inspiratory muscle training on dyspnoea in severe COPD patients during pulmonary rehabilitation: controlled randomised trial. Eur Respir J. 2018;51(1):1701107. doi: 10.1183/13993003.01107-2017, PMID 29371379.
Chuang HY, Chang HY, Fang YY, Guo SE. The effects of threshold inspiratory muscle training in patients with chronic obstructive pulmonary disease: a randomised experimental study. J Clin Nurs. 2017;26(23-24):4830-8. doi: 10.1111/jocn.13841, PMID 28382660.
Charususin N, Gosselink R, Decramer M, Demeyer H, MC Connell A, Saey D. Randomised controlled trial of adjunctive inspiratory muscle training for patients with COPD. Thorax. 2018;73(10):942-50. doi: 10.1136/thoraxjnl-2017-211417, PMID 29914940.
Kumar KS, Kumaresan C, Anantharaj R. Development and comparison of orally inhalable sustained release formulations for three respiratory drugs for asthma. Adv Chem. 2016;12(25):5679-99. doi: 10.24297/jac.v12i25.4658.
James AC, Stahlhofen W, Rudolf G, Annexe D. Deposition of inhaled particles. Ann ICRP. 1994;24:231-99.
Peng T, Lin S, Niu B, Wang X, Huang Y, Zhang X. Influence of physical properties of carrier on the performance of dry powder inhalers. Acta Pharm Sin B. 2016;6(4):308-18. doi: 10.1016/j.apsb.2016.03.011, PMID 27471671.
Rotahaler (For Cipla Rotacaps)-4NRX (UK). Available from: https://www.4nrx-uk.md/accessories/rota haler.html. [Last accessed on 02 Apr 2025].
Hira D, Koide H, Nakamura S, Okada T, Ishizeki K, Yamaguchi M. Assessment of inhalation flow patterns of soft mist inhaler co-prescribed with dry powder inhaler using inspiratory flow meter for multi inhalation devices. Plos One. 2018;13(2):e0193082. doi: 10.1371/journal.pone.0193082, PMID 29462195.
Ungaro F, Vanbever R. Improving the efficacy of inhaled drugs for severe lung diseases: emerging pulmonary delivery strategies. Adv Drug Deliv Rev. 2014 Aug;75:1-2. doi: 10.1016/j.addr.2014.08.001, PMID 25109852.
Chang RY, Chow MY, Khanal D, Chen D, Chan HK. Dry powder pharmaceutical biologics for inhalation therapy. Adv Drug Deliv Rev. 2021 May;172:64-79. doi: 10.1016/j.addr.2021.02.017, PMID 33705876.
Dierick BJ, Eikholt AA, Van DE Hei SJ, Muris JW, Kerstjens HA, Van Boven JF. Reshaping respiratory care: potential advances in inhaled pharmacotherapy in asthma. Expert Opin Pharmacother. 2024;25(11):1507-16. doi: 10.1080/14656566.2024.2389258, PMID 39099418.
Gaikwad SS, Pathare SR, More MA, Waykhinde NA, Laddha UD, Salunkhe KS. Dry powder inhaler with the technical and practical obstacles and forthcoming platform strategies. J Control Release. 2023 Mar;355:292-311. doi: 10.1016/j.jconrel.2023.01.083, PMID 36739908.
Mehta PP. Dry powder inhalers: a concise summary of the electronic monitoring devices. Ther Deliv. 2021;12(1):1-6. doi: 10.4155/tde-2020-0091, PMID 32873214.
Labiris NR, Dolovich MB. Pulmonary drug delivery. Part I: physiological factors affecting therapeutic effectiveness of aerosolized medications. Br J Clin Pharmacol. 2003;56(6):588-99. doi: 10.1046/j.1365-2125.2003.01892.x, PMID 14616418.
Kumar R, Mehta P, Shankar KR, Rajora MA, Mishra YK, Mostafavi E. Nanotechnology assisted metered dose inhalers (MDIs) for high-performance pulmonary drug delivery applications. Pharm Res. 2022;39(11):2831-55. doi: 10.1007/s11095-022-03286-y, PMID 35552983.
Magramane S, Vlahovic K, Gordon P, Kallai Szabo N, Zelko R, Antal I. Inhalation dosage forms: a focus on dry powder inhalers and their advancements. Pharmaceuticals (Basel). 2023;16(12):1658. doi: 10.3390/PH16121658, PMID 38139785.
Ciphaler® device by Cipla EU ltd-rightbreathe. Available from: https://www.rightbreathe.com/?s=anddevice_type=anddrug_class=anddrug_name=anddevice_type=andcopd_licence=1.
Arora P, Kumar L, Vohra V, Sarin R, Jaiswal A, Puri MM. Evaluating the technique of using inhalation device in COPD and bronchial asthma patients. Respir Med. 2014;108(7):992-8. doi: 10.1016/j.rmed.2014.04.021, PMID 24873874.
DE Pietro M, Gilbert I, Millette LA, Riebe M. Inhalation device options for the management of chronic obstructive pulmonary disease. Postgrad Med. 2018;130(1):83-97. doi: 10.1080/00325481.2018.1399042, PMID 29210318.
Mansour HM, Muralidharan P, Hayes D. Inhaled nanoparticulate systems: composition manufacture and aerosol delivery. J Aerosol Med Pulm Drug Deliv. 2024;37(4):202-18. doi: 10.1089/jamp.2024.29117.mk, PMID 39172256.
Digihaler Support Center. Digihaler inhaler FAQs. Available from: https://www.digihaler.com/support/using-my-inhaler. [Last accessed on 22 Aug 2024].
Pramanik S, Mohanto S, Manne R. Nanoparticle-based drug delivery system: the magic bullet for the treatment of chronic pulmonary diseases. Cite this. Mol Pharm. 2021;18(10):3671-718.
Van SD, Barrett M, Humblet O. Randomized controlled study of the impact of a mobile health tool on asthma SABA use control and adherence. Eur Respir J. 2016;48:PA1018.
Haubermann S, Arendsen LJ, Pritchard JN. Smart dry powder inhalers and intelligent adherence management. Adv Drug Deliv Rev. 2022;191:114580. doi: 10.1016/j.addr.2022.114580, PMID 36273513.
Pothirat C, Chaiwong W, Limsukon A, Phetsuk N, Chetsadaphan N, Choomuang W. Real-world observational study of the evaluation of inhaler techniques in asthma patients. Asian Pac J Allergy Immunol. 2021;39(2):96-102. doi: 10.12932/AP-210618-0348, PMID 30660168.
Poplicean E, Crisan AF, Tudorache E, Hogea P, Mladin R, Oancea C. Unlocking better asthma control: a narrative review of adherence to asthma therapy and innovative monitoring solutions. J Clin Med. 2024;13(22):6699. doi: 10.3390/jcm13226699, PMID 39597843.
Bhattarai A, Shakya R, Bista D. Impact of pharmacist led intervention on adherence to inhalers inhalation technique and disease control among asthma/COPD patients in a resource limited center: an interventional study. Patient Preference Adherence. 2024;18:1395-408. doi: 10.2147/PPA.S460810, PMID 38974680.
Furman EG, Khuzina EA. Age-related features of the choice of inhalers in children and adolescents with bronchial asthma and other respiratory diseases. Meditsinskiy Sovet. 2024;18:92-9.
Dhoble S, Kapse A, Ghegade V, Chogale M, Ghodake V, Patravale V. Design development and technical considerations for dry powder inhaler devices. Drug Discov Today. 2024;29(5):103954. doi: 10.1016/j.drudis.2024.103954, PMID 38531423.
Lavorini F. Easyhaler®: an overview of an inhaler device for day to day use in patients with asthma and chronic obstructive pulmonary disease. Drugs Context. 2019 Jun 5;8:212596. doi: 10.7573/dic.212596, PMID 31210773.
Larsson K, Bjermer L, Svartengren M. The importance of selecting the right type of inhaler for patients with asthma and chronic obstructive pulmonary disease (COPD). Lakartidningen. 2019;116:FF76. PMID 30720857.
Aggarwal B, Gogtay J. Use of pressurized metered dose inhalers in patients with chronic obstructive pulmonary disease: review of evidence. Expert Rev Respir Med. 2014;8(3):349-56. doi: 10.1586/17476348.2014.905916, PMID 24802511.
Mekov E, Petkov R. Smart inhalers: transforming respiratory disease management through artificial intelligence. Gazz Med Ital Arch Sci Med. 2024;183(9):765-8. doi: 10.23736/S0393-3660.24.05533-5.
Chrystyn H, Audibert R, Keller M, Quaglia B, Vecellio L, Roche N. Real life inhaler adherence and technique: time to get smarter. Respir Med. 2019 Oct-Nov;158:24-32. doi: 10.1016/j.rmed.2019.09.008, PMID 31563027.
Abou El Nour KM, Eftaiha A, Al Warthan A. Synthesis and applications of silver nanoparticles. Arab J Chem. 2010 Jul;3(3):135-40. doi: 10.1016/j.arabjc.2010.04.008.
Pandey N, Dhiman S, Srivastava T, Majumder S. Transition metal oxide nanoparticles are effective in inhibiting lung cancer cell survival in the hypoxic tumor microenvironment. Chem Biol Interact. 2016;254:221-30. doi: 10.1016/j.cbi.2016.06.006, PMID 27270449.
Kawashima Y. Nanoparticulate systems for improved drug delivery; 2001. Available from: www.elsevier.com/locate/drugdeliv.
Doroudian M, Armstrong ME, Donnelly SC. Nano-based therapies for acute and chronic lung diseases; 2023. p. 271-86.
Ezike TC, Okpala US, Onoja UL, Nwike CP, Ezeako EC, Okpara OJ. Advances in drug delivery systems challenges and future directions. Heliyon Heliyon. 2023;9(6):e17488. doi: 10.1016/j.heliyon.2023.e17488, PMID 37416680.
Afzal O, Altamimi AS, Nadeem MS, Alzarea SI, Almalki WH, Tariq A. Nanoparticles in drug delivery: from history to therapeutic applications. Nanomaterials. 2022;12(24):4494. doi: 10.3390/nano12244494, PMID 36558344.
DE Rubis G, Paudel KR, Manandhar B, Singh SK, Gupta G, Malik R. Agarwood oil nanoemulsion attenuates cigarette smoke-induced inflammation and oxidative stress markers in bci-ns1.1 airway epithelial cells. Nutrients. 2023;15(4):1019. doi: 10.3390/nu15041019, PMID 36839377.
Saxena J, Bisen M, Misra A, Srivastava VK, Kaushik S, Siddiqui AJ. Targeting COPD with PLGA based nanoparticles: current status and prospects. Bio Med Res Int. 2022;2022:5058121. doi: 10.1155/2022/5058121, PMID 35309178.
Zhang L, GU FX, Chan JM, Wang AZ, Langer RS, Farokhzad OC. Nanoparticles in medicine: therapeutic applications and developments. Clin Pharmacol Ther. 2008;83(5):761-9. doi: 10.1038/sj.clpt.6100400, PMID 17957183.
Yhee JY, Im J, Nho RS. Advanced therapeutic strategies for chronic lung disease using nanoparticle based drug delivery. J Clin Med. 2016;5(9):82. doi: 10.3390/JCM5090082, PMID 27657144.
Schuster BS, Suk JS, Woodworth GF, Hanes J. Nanoparticle diffusion in respiratory mucus from humans without lung disease. Biomaterials. 2013;34(13):3439-46. doi: 10.1016/j.biomaterials.2013.01.064, PMID 23384790.
Lim Soo PL, Eisenberg A. Preparation of block copolymer vesicles in solution. J Polym Sci B Polym Phys. 2004;42(6):923-38. doi: 10.1002/polb.10739.
Vert M, Doi Y, Hellwich KH, Hess M, Hodge P, Kubisa P. Terminology for biorelated polymers and applications (IUPAC recommendations 2012). Pure Appl Chem. 2012;84(2):377-410. doi: 10.1351/PAC-REC-10-12-04.
Pham DT, Chokamonsirikun A, Phattaravorakarn V, Tiyaboonchai W. Polymeric micelles for pulmonary drug delivery: a comprehensive review. J Mater Sci. 2021;56(3):2016-36. doi: 10.1007/s10853-020-05361-4.
Mulhall P, Criner G. Non-pharmacological treatments for COPD. Respirology. 2016;21(5):791-809. doi: 10.1111/resp.12782, PMID 27099216.
Mishra B, Singh J. Novel drug delivery systems and significance in respiratory diseases. In: Targeting chronic inflammatory lung diseases using advanced drug delivery systems. Elsevier; 2020. p. 57-95. doi: 10.1016/B978-0-12-820658-4.00004-2.
Sriram Mishra A, Sugumaran A, Abimanyu S. Nanoparticulate delivery systems for the effective treatment of COPD; 2021. Available from: http://annalsofrscb.ro.
Khan OF, Zaia EW, Jhunjhunwala S, Xue W, Cai W, Yun DS. Dendrimer-inspired nanomaterials for the in vivo delivery of siRNA to lung vasculature. Nano Lett. 2015;15(5):3008-16. doi: 10.1021/nl5048972, PMID 25789998.
Liposomes: a short review. Available from: https://www.researchgate.net/publication/286860779_Liposomes_A_short_review. [Last accessed on 24 Aug 2024].
Pierre MB, Dos Santos Miranda Costa I. Liposomal systems as drug delivery vehicles for dermal and transdermal applications. Arch Dermatol Res. 2011;303(9):607-21. doi: 10.1007/s00403-011-1166-4, PMID 21805180.
Danhier F, Feron O, Preat V. To exploit the tumor microenvironment: passive and active tumor targeting of nanocarriers for anti-cancer drug delivery. J Control Release. 2010;148(2):135-46. doi: 10.1016/j.jconrel.2010.08.027, PMID 20797419.
Guo L, Fan L, Ren J, Pang Z, Ren Y, LI J. Combination of TRAIL and actinomycin D liposomes enhances antitumor effect in non-small cell lung cancer. Int J Nanomedicine. 2012 Mar 19;7:1449-60. doi: 10.2147/IJN.S24711, PMID 22619505.
Kellaway IW, Farr SJ. Liposomes as drug delivery systems to the lung. Adv Drug Deliv Rev. 1990;5(1-2):149-61. doi: 10.1016/0169-409X(90)90012-H.
Kraft JC, Freeling JP, Wang Z, HO RJ. Emerging research and clinical development trends of liposome and lipid nanoparticle drug delivery systems. J Pharm Sci. 2014;103(1):29-52. doi: 10.1002/jps.23773, PMID 24338748.
Meng H, XU Y. Pirfenidone loaded liposomes for lung targeting: preparation and in vitro/in vivo evaluation. Drug Des Dev Ther. 2015 Jun 30;9:3369-76. doi: 10.2147/DDDT.S84046, PMID 26185416.
Chennakesavulu S, Mishra A, Sudheer A, Sowmya C, Suryaprakash Reddy C, Bhargav E. Pulmonary delivery of liposomal dry powder inhaler formulation for effective treatment of idiopathic pulmonary fibrosis. Asian J Pharm Sci. 2018;13(1):91-100. doi: 10.1016/j.ajps.2017.08.005, PMID 32104382.
Wang Q, WU P, Ren W, Xin K, Yang Y, Xie C. Comparative studies of salinomycin loaded nanoparticles prepared by nanoprecipitation and single emulsion method. Nanoscale Res Lett. 2014;9(1):351. doi: 10.1186/1556-276X-9-351, PMID 25147486.
Rudokas M, Najlah M, Alhnan MA, Elhissi A. Liposome delivery systems for inhalation: a critical review highlighting formulation issues and anticancer applications. Med Princ Pract. 2016;25 Suppl 2:60-72. doi: 10.1159/000445116, PMID 26938856.
Weber S, Zimmer A, Pardeike J. Solid lipid nanoparticles (SLN) and nanostructured lipid carriers (nlc) for pulmonary application: a review of the state of the art. Eur J Pharm Biopharm. 2014;86(1):7-22. doi: 10.1016/j.ejpb.2013.08.013, PMID 24007657.
Lopez KL, Ravasio A, Gonzalez Aramundiz JV, Zacconi FC. Solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC) prepared by microwave and ultrasound-assisted synthesis: promising green strategies for the nanoworld. Pharmaceutics. 2023;15(5):1333. doi: 10.3390/pharmaceutics15051333, PMID 37242575.
Shi C, Guo K, Zhang L, Guo Y, Feng Y, Cvijic S. In vitro and In vivo evaluation of inhalable ciprofloxacin sustained release formulations. Pharmaceutics. 2023;15(9):2287. doi: 10.3390/pharmaceutics15092287, PMID 37765256.
Loira Pastoriza C, Todoroff J, Vanbever R. Delivery strategies for sustained drug release in the lungs. Adv Drug Deliv Rev. 2014 Aug;75:81-91. doi: 10.1016/j.addr.2014.05.017, PMID 24915637.
MC Clements DJ. Edible nanoemulsions: fabrication properties and functional performance. Soft Matter. 2011;7(6):2297-316. doi: 10.1039/C0SM00549E.
Shafiq S, Shakeel F, Talegaonkar S, Ahmad FJ, Khar RK, Ali M. Development and bioavailability assessment of ramipril nanoemulsion formulation. Eur J Pharm Biopharm. 2007;66(2):227-43. doi: 10.1016/j.ejpb.2006.10.014, PMID 17127045.
Bali V, Ali M, Ali J. Novel nanoemulsion for minimizing variations in bioavailability of ezetimibe. J Drug Target. 2010;18(7):506-19. doi: 10.3109/10611860903548362, PMID 20067438.
Wang X, Jiang Y, Wang YW, Huang MT, HO CT, Huang Q. Enhancing anti-inflammation activity of curcumin through O/W nanoemulsions. Food Chem. 2008;108(2):419-24. doi: 10.1016/j.foodchem.2007.10.086, PMID 26059118.
Patravale VB, Mandawgade SD. Novel cosmetic delivery systems: an application update. Int J Cosmet Sci. 2008;30(1):19-33. doi: 10.1111/j.1468-2494.2008.00416.x, PMID 18377627.
Beloqui A, Solinis MA, Delgado A, Evora C, Del Pozo Rodriguez A, Rodriguez-Gascon A. Biodistribution of nanostructured lipid carriers (NLCS) after intravenous administration to rats: influence of technological factors. Eur J Pharm Biopharm. 2013;84(2):309-14. doi: 10.1016/j.ejpb.2013.01.029, PMID 23461861.
Khurana S, Jain NK, Bedi PM. Development and characterization of a novel controlled release drug delivery system based on nanostructured lipid carriers gel for meloxicam. Life Sci. 2013;93(21):763-72. doi: 10.1016/j.lfs.2013.09.027, PMID 24113071.
Fathi HA, Allam A, Elsabahy M, Fetih G, El-Badry M. Nanostructured lipid carriers for improved oral delivery and prolonged antihyperlipidemic effect of simvastatin. Colloids Surf B Biointerfaces. 2018 Feb 1;162:236-45. doi: 10.1016/j.colsurfb.2017.11.064, PMID 29197789.
Salvi VR, Pawar P. Nanostructured lipid carriers (NLC) system: a novel drug targeting carrier. J Drug Deliv Sci Technol. 2019 Jun;51:255-67. doi: 10.1016/j.jddst.2019.02.017.
Graczyk H, Bryan LC, Lewinski N, Suarez G, Coullerez G, Bowen P. Physicochemical characterization of nebulized superparamagnetic iron oxide nanoparticles (SPIONs). J Aerosol Med Pulm Drug Deliv. 2015;28(1):43-51. doi: 10.1089/jamp.2013.1117, PMID 24801912.
Verma NK, Crosbie Staunton K, Satti A, Gallagher S, Ryan KB, Doody T. Magnetic core shell nanoparticles for drug delivery by nebulization. J Nanobiotechnology. 2013;11:1. doi: 10.1186/1477-3155-11-1, PMID 23343139.
Han X, LI Y, Liu W, Chen X, Song Z, Wang X. The applications of magnetic particle imaging: from cell to body. Diagnostics. 2020;10(10):800. doi: 10.3390/diagnostics10100800, PMID 33050139.
Nishimoto K, Mimura A, Aoki M. Application of magnetic particle imaging to pulmonary imaging using nebulized magnetic nanoparticles. Open J Med Imaging. 2015;5:49-55.
Ali A, Zafar H, Zia M, Ul Haq I, Phull AR, Ali JS. Synthesis characterization applications and challenges of iron oxide nanoparticles. Nanotechnol Sci Appl. 2016 Aug 19;9:49-67. doi: 10.2147/NSA.S99986, PMID 27578966.
Verma NK, Crosbie Staunton K, Satti A, Gallagher S, Ryan KB, Doody T. Magnetic core-shell nanoparticles for drug delivery by nebulization. J Nanobiotechnology. 2013;11:1. doi: 10.1186/1477-3155-11-1, PMID 23343139.
Yang Z, Wang D, Zhang C, Liu H, Hao M, Kan S. The applications of gold nanoparticles in the diagnosis and treatment of gastrointestinal cancer. Front Oncol. 2021;11:819329. doi: 10.3389/fonc.2021.819329, PMID 35127533.
Nguyen KT, Zhao Y. Engineered hybrid nanoparticles for on demand diagnostics and therapeutics. Acc Chem Res. 2015;48(12):3016-25. doi: 10.1021/acs.accounts.5b00316, PMID 26605438.
Hadinoto K, Sundaresan A, Cheow WS. Lipid polymer hybrid nanoparticles as a new generation therapeutic delivery platform: a review. Eur J Pharm Biopharm. 2013;85(3 Pt A):427-43. doi: 10.1016/j.ejpb.2013.07.002, PMID 23872180.
Sgorla D, Bunhak EJ, Cavalcanti OA, Fonte P, Sarmento B. Exploitation of lipid-polymeric matrices at nanoscale for drug delivery applications. Expert Opin Drug Deliv. 2016;13(9):1301-9. doi: 10.1080/17425247.2016.1182492, PMID 27110648.
Clawson C, Ton L, Aryal S, FU V, Esener S, Zhang L. Synthesis and characterization of lipid polymer hybrid nanoparticles with pH-triggered poly(ethylene glycol) shedding. Langmuir. 2011;27(17):10556-61. doi: 10.1021/la202123e, PMID 21806013.
Zhang L, Feng Q, Wang J, Zhang S, Ding B, Wei Y. Microfluidic synthesis of hybrid nanoparticles with controlled lipid layers: understanding flexibility-regulated cell nanoparticle interaction. ACS Nano. 2015;9(10):9912-21. doi: 10.1021/acsnano.5b05792, PMID 26448362.
Zhang L, Zhang L. Lipid polymer hybrid nanoparticles: synthesis characterization and applications. Nano Life. 2010;1:163-73. doi: 10.1142/S179398441000016X.
Ragelle H, Colombo S, Pourcelle V, Vanvarenberg K, Vandermeulen G, Bouzin C. Intracellular siRNA delivery dynamics of integrin targeted pegylated chitosan-poly(ethylene imine) hybrid nanoparticles: a mechanistic insight. J Control Release. 2015 Aug 10;211:1-9. doi: 10.1016/j.jconrel.2015.05.274, PMID 25989603.
Hoppentocht M, Hagedoorn P, Frijlink HW, DE Boer AH. Technological and practical challenges of dry powder inhalers and formulations. Adv Drug Deliv Rev. 2014 Aug;75:18-31. doi: 10.1016/j.addr.2014.04.004, PMID 24735675.
Kulkarni A, Jagnade V, Hole K. Effect of formulation excipients on aerosolisation performance of budesonide. Indo Am J Pharm Res. 2017;7(11):909-19.
Sahab Uddin M, Hossain M, Al Mamun A. Pharmacopoeial standards and specifications for pharmaceutical aerosols: in process and finished products quality control tests. Equal Contributors Advances in Research. 2016;6(3):1-12. doi: 10.9734/AIR/2016/22442.
Agu RU, Ugwoke MI. In vitro and in vivo testing methods for respiratory drug delivery. Expert Opin Drug Deliv. 2011;8(1):57-69. doi: 10.1517/17425247.2011.543896, PMID 21174605.
HO KK, Kellaway IW, Tredree R. Particle size analysis of nebulised aerosols using Fraunhofer laser diffraction and inertial compaction methods. J Pharm Pharmacol. 2011;38(S12):26P. doi: 10.1111/j.2042-7158.1986.tb14255.x.
Radivojev S, Zellnitz S, Paudel A, Frohlich E. Searching for physiologically relevant in vitro dissolution techniques for orally inhaled drugs. Int J Pharm. 2019 Feb 10;556:45-56. doi: 10.1016/j.ijpharm.2018.11.072, PMID 30529665.
Eedara BB, Tucker IG, Das SC. In vitro dissolution testing of respirable size anti-tubercular drug particles using a small volume dissolution apparatus. Int J Pharm. 2019 Mar 25;559:235-44. doi: 10.1016/j.ijpharm.2019.01.035, PMID 30684598.
Nokhodchi A, Chavan S, Ghafourian T. In vitro dissolution and permeability testing of inhalation products: challenges and advances. Pharmaceutics. 2023;15(3):983. doi: 10.3390/pharmaceutics15030983, PMID 36986844.
May S, Jensen B, Wolkenhauer M, Schneider M, Lehr CM. Dissolution techniques for in vitro testing of dry powders for inhalation. Pharm Res. 2012;29(8):2157-66. doi: 10.1007/s11095-012-0744-2, PMID 22528980.
Davies NM, Feddah MR. A novel method for assessing dissolution of aerosol inhaler products. Int J Pharm. 2003;255(1-2):175-87. doi: 10.1016/s0378-5173(03)00091-7, PMID 12672613.
Salama RO, Traini D, Chan HK, Young PM. Preparation and characterisation of controlled release co-spray dried drug polymer microparticles for inhalation 2: evaluation of in vitro release profiling methodologies for controlled release respiratory aerosols. Eur J Pharm Biopharm. 2008;70(1):145-52. doi: 10.1016/j.ejpb.2008.04.009, PMID 18534832.
Marques MR, Loebenberg R, Almukainzi M. Simulated biological fluids with possible application in dissolution testing. Dissolut Technol. 2011;18:15-28.
Moss OR. Simulants of lung interstitial fluid. Health Phys. 1979;36(3):447-8. PMID 489300.
Hassoun M, Royall PG, Parry M, Harvey RD, Forbes B. Design and development of a biorelevant simulated human lung fluid. J Drug Deliv Sci Technol. 2018 Oct;47:485-91. doi: 10.1016/j.jddst.2018.08.006, PMID 30283501.
Published
How to Cite
Issue
Section
Copyright (c) 2025 SUPRAJA A., GUNDAWAR RAVI, TANVI PAINGINKAR, GIRISH PAI K., VIRENDRA S. LIGADE, K. SREEDHARA RANGANATH PAI, VASANTHARAJU SG, MUDDUKRISHNA BS
This work is licensed under a Creative Commons Attribution 4.0 International License.
